marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-13-2024
Adaptimmune Therapeutics plc Financial Statements 2011-2024 | ADAP
Annual Financial Statements Adaptimmune Therapeutics plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.05 B | 1.26 B | 2.73 B | 4.67 B | 2.52 T | 2.72 T | 4.57 T | 1.78 T | 6.41 B | - | - | - | - |
Shares |
1.21 B | 967 M | 935 M | 855 M | 630 B | 584 B | 516 B | 425 B | 425 M | - | - | - | - |
Historical Prices |
1.7 | 1.3 | 2.92 | 5.46 | 3.9 | 4.87 | 8.63 | 4.31 | 7.07 | - | - | - | - |
Net Income |
-114 M | -165 M | -158 M | -130 M | -137 M | -95.5 M | -70.1 M | -71.6 M | -17.5 M | -12.7 M | -8.46 M | - | - |
Revenue |
60.3 M | 27.1 M | 6.15 M | 3.96 M | 1.12 M | 59.5 M | 37.8 M | 14.2 M | 8.71 M | 605 K | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | 1.12 M | 59.5 M | 37.8 M | 14.2 M | - | - | - | - | - |
Operating Income |
-140 M | -164 M | -162 M | -133 M | -140 M | -82.4 M | -80.7 M | -72.8 M | -24.6 M | -11.5 M | -8.75 M | - | - |
Interest Expense |
-807 K | -536 K | 3.85 M | 1.16 M | 75 K | -15.5 M | 8.74 M | 1 M | 2.32 M | -5 K | 9 K | - | - |
EBITDA |
-130 M | -159 M | -157 M | -127 M | -132 M | -74.6 M | -75.2 M | -69.5 M | -18.1 M | -14.1 M | -9.29 M | - | - |
Operating Expenses |
- | - | - | - | 141 M | 142 M | 118 M | 87 M | 33.8 M | 15 M | - | - | - |
General and Administrative Expenses |
73.5 M | 63.4 M | 57.3 M | 45.8 M | 43.4 M | 43.6 M | 31.1 M | 23.2 M | 11.3 M | 2.73 M | 1.21 M | - | - |
All numbers in USD currency
Quarterly Income Statement Adaptimmune Therapeutics plc
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.53 B | 1.53 B | 1.45 B | 1.36 B | 1.36 B | 1.11 B | 991 M | 987 M | 981 M | 963 M | 940 M | 938 M | 937 M | 934 M | 931 M | 929 M | 928 M | 823 M | 740 M | 631 M | 631 M | 629 M | 628 M | 627 M | 582 M | 565 M | 562 M | 562 M | 561 M | 557 M | 429 M | 425 M | 425 M | 425 M | 425 M | 425 M | 425 M | 317 M | 181 M | - | - | 181 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-17.6 M | 69.5 M | -48.5 M | - | -45.6 M | -21.4 M | 1.04 M | - | -41.4 M | -44.5 M | -50.3 M | - | -42.4 M | -39.1 M | -37.8 M | - | -35.4 M | -29.9 M | -28.2 M | - | -39.3 M | -41.1 M | -27.4 M | - | 5.24 M | -43.8 M | -20.7 M | - | -878 K | -20.2 M | -21.8 M | - | -18.5 M | -22.1 M | -15.6 M | - | -6.24 M | -14.6 M | -23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
40.9 M | 128 M | 5.68 M | - | 7.32 M | 5.13 M | 47.6 M | - | 7.01 M | 5.54 M | 3.58 M | - | 1.2 M | 3.1 M | 434 K | - | 1.19 M | 502 K | 761 K | - | 237 K | 157 K | - | - | 40.8 M | 9.04 M | 8.2 M | - | 27.2 M | 3.52 M | 2.86 M | - | 2.42 M | 328 K | 2.92 M | - | 4.95 M | 2.78 M | 8.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-14.7 M | 68.7 M | -49.3 M | - | -46.6 M | -44.9 M | 1.66 M | - | -43 M | -43.8 M | -50 M | - | -42.2 M | -39.3 M | -37.9 M | - | -35.9 M | -30.3 M | -29.8 M | - | -40.1 M | -35.5 M | -33.8 M | - | 7.02 M | -28.9 M | -28.7 M | - | -4.96 M | -23.8 M | -22.2 M | - | -18.6 M | -22.7 M | -16.8 M | - | -8.31 M | -11.1 M | -26.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-3.09 M | 497 K | -61 K | - | -324 K | 501 K | -671 K | - | 1.64 M | -655 K | 12 K | - | -237 K | 54 K | -1 K | - | -1.69 M | -749 K | 937 K | - | 291 K | -6.28 M | 5.43 M | - | -2.25 M | -15.4 M | 7.13 M | - | 8 K | 6 K | 430 K | - | -61 K | 607 K | 1.05 M | - | 1.85 M | -3.5 M | 2.87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | -46.5 M | - | - | - | 3.32 M | - | -39 M | -43.8 M | -48.6 M | - | -37.8 M | -39.3 M | -36.5 M | - | -30.7 M | -26.7 M | -28.1 M | - | -34.7 M | -31.9 M | -32 M | - | 12.3 M | -25.4 M | -27 M | - | -3.56 M | -22.7 M | -21.2 M | - | -17.8 M | -21.9 M | -16.1 M | - | -7.84 M | -10.8 M | -25.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.7 M | - | - | - | 35.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
21.3 M | 19.1 M | 19.7 M | - | 16.2 M | 20.1 M | 20.4 M | - | 16.8 M | 14.6 M | 16.8 M | - | 15.2 M | 13.5 M | 13.8 M | - | 13 M | 10.3 M | 9.26 M | - | 10.7 M | 10.1 M | 11.8 M | - | 10.3 M | 11.3 M | 11.2 M | - | 8.11 M | 7.71 M | 6.46 M | - | 5.42 M | 6.17 M | 5.27 M | - | 4.4 M | 5.49 M | 11.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency